招银国际发表报告指，诺诚健华(09969.HK) 今年首九个月收入达21亿元人民币(下同)，按年升88.2%。期内药品销售贡献14.5亿元，按年升41.5%，相当于该行全年预测的73%，符合预期。单计第三季，收入达9.62亿元，其中药品销售5.31亿元，按年升38.6%、按季升13.8%。首九个月净利6.48亿元，对比去年同期亏损7,200万元，经营现金流亦转正至2.2亿元。该行指，近期与礼来达成...
Source Link招银国际发表报告指，诺诚健华(09969.HK) 今年首九个月收入达21亿元人民币(下同)，按年升88.2%。期内药品销售贡献14.5亿元，按年升41.5%，相当于该行全年预测的73%，符合预期。单计第三季，收入达9.62亿元，其中药品销售5.31亿元，按年升38.6%、按季升13.8%。首九个月净利6.48亿元，对比去年同期亏损7,200万元，经营现金流亦转正至2.2亿元。该行指，近期与礼来达成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.